P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesis
Hepatology · 2023-05 · 77 (5) · 1499-1511
DOI: 10.1002/hep.32518 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology, online erschienen am 17.04.2023. Verfasst von Yahui Zhu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hubei Key Laboratory of Cell Homeostasis , College of Life Sciences , Wuhan University , Wuhan , China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 78-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background and Aims: Cholesterol ester (CE) biosynthesis and homeostasis play critical roles in many cancers, including HCC, but their exact mechanistic contributions to HCC disease development require further study. Approach and Results: Here, we report on a proposed role of tumor suppressor P53 in its repressing ubiquitin‐specific peptidase 19 (USP19) and sterol O‐acyltransferase (SOAT) 1, which maintains CE homeostasis. USP19 enhances cholesterol esterification and contributes to hepatocarcinogenesis (HCG) by deubiquitinating and stabilizing SOAT1. Loss of either SOAT1 or USP19 dramatically attenuates cholesterol esterification and HCG in P53‐deficient mice fed with either a normal chow diet or a high‐cholesterol, high‐fat diet (HCHFD). SOAT1 inhibitor avasimibe has more inhibitory effect on HCC progression in HCHFD‐maintained P53‐deficient mice when compared to the inhibitors of de novo cholesterol synthesis. Consistent with our findings in the mouse model, the P53‐USP19‐SOAT1 signaling axis is also dysregulated in human HCCs. Conclusions: Collectively, our findings demonstrate that SOAT1 participates in HCG by increasing cholesterol esterification, thus indicating that SOAT1 is a potential biomarker and therapeutic target in P53‐deficient HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hubei Key Laboratory of Cell Homeostasis , College of Life Sciences , Wuhan University , Wuhan , China.
- Frontier Science Center for Immunology and Metabolism , Medical Research Institute , Wuhan University , Wuhan , China.
- School of Medicine , Chongqing University , Chongqing , China.
- Division of Hematology/Oncology , Children's Hospital of Pittsburgh of UPMC , The Department of Microbiology and Molecular Genetics , The Pittsburgh Liver Research Center and The Hillman Cancer Center of UPMC , The Univ…
- Department of Pharmacology , School of Medicine , University of California, San Diego , La Jolla , California , USA.
- Department of Laboratory Medicine , Zhongnan Hospital of Wuhan University , Wuhan , China.
Förderung
- NCI NIH HHS
Zitieren
APA
Zhu, Y., Gu, L., Lin, X., Zhou, X., Lu, B., Liu, C., Li, Y., Prochownik, E. V., Karin, M., Wang, F., & Li, Y. (2023). P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesis. Hepatology, 77(5), 1499-1511. https://doi.org/10.1002/hep.32518
Vancouver
Zhu Y, Gu L, Lin X, Zhou X, Lu B, Liu C, et al. P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesis. Hepatology. 2023;77(5):1499-1511. doi:10.1002/hep.32518
BibTeX
@article{Zhu2023,
author = {Zhu, Yahui and Gu, Li and Lin, Xi and Zhou, Xinyi and Lu, Bingjun and Liu, Cheng and Li, Yajun and Prochownik, Edward V and Karin, Michael and Wang, Fubing and Li, Youjun},
title = {P53 deficiency affects cholesterol esterification to exacerbate hepatocarcinogenesis},
journal = {Hepatology},
year = {2023},
volume = {77},
number = {5},
pages = {1499--1511},
doi = {10.1002/hep.32518}
}
EUVIMED